Compare
Glucotrack, Inc. vs RenovoRx, Inc. vs Bluejay Diagnostics, Inc. vs Sintx Technologies, Inc.
| Latest fiscal year | Glucotrack, Inc. GCTKRevenue covers only part of its income (partial revenue) | RenovoRx, Inc. RNXT | Bluejay Diagnostics, Inc. BJDX | Sintx Technologies, Inc. SINT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $1.12M | n/a | $1.02M |
| Revenue growth (YoY) | n/a | n/m | n/a | -64.7% |
| Gross margin | n/a | 70.9% | n/a | 45.3% |
| Operating margin | n/a | n/m | n/a | n/m |
| Net margin | n/a | -994.5% | n/a | n/m |
| Net income | -$19.39M | -$11.17M | -$6.85M | -$10.36M |
| EPS (Diluted) | $31.22 | -$0.32 | -$15.25 | -$6.16 |
| Operating cash flow | -$15.24M | -$10.97M | -$6.05M | -$8.57M |
| Free cash flow | -$15.34M | -$10.97M | -$6.23M | -$8.76M |
| Cash & equivalents | $7.38M | $7.02M | $5.16M | $4.14M |
| Total assets | $7.84M | $8.10M | $7.12M | $9.51M |
| Total liabilities | $5.01M | $2.67M | $1.14M | $6.58M |
| Shareholders' equity | $2.83M | $5.42M | $5.98M | $2.93M |
| Return on year-end equity | -685.6% | -206.0% | -114.6% | -353.8% |
| Shares outstanding | 910.7K | 36.61M | 604.5K | 3.97M |
Revenue, most recent five fiscal years
| Fiscal year | Glucotrack, Inc. | RenovoRx, Inc. | Bluejay Diagnostics, Inc. | Sintx Technologies, Inc. |
|---|---|---|---|---|
| Latest | n/a | $1.12M Ended 2025-12-31 | $249.0K Ended 2022-12-31 | $1.02M Ended 2025-12-31 |
| 1 year earlier | n/a | $43.0K Ended 2024-12-31 | n/a | $2.89M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $2.63M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $1.56M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $606.0K Ended 2021-12-31 |